Manufacturers of AlzheimAlert report the non-invasive test has proven accurate in actual clinical settings, offering a reliable aid in early diagnosis of Alzheimer's disease.

The test's maker, Nymox Pharmaceutical Corporation, presented the results at the 2002 Annual Scientific Meeting of the American Geriatrics Society.

"These studies are based on the actual experiences of U.S. physicians in their daily practices and show the utility and value of AlzheimAlert in the clinical setting," said Dr. Michael Munzar, Nymox's Medical Director. "AlzheimAlert provides physicians with a proven non-invasive tool to help with the difficult task of making an early and accurate diagnosis of Alzheimer's disease."

The test was performed on 144 Alzheimer's patients and non-Alzheimer control patients. Researchers tested each sample in triplicate without knowledge of the diagnosis.

Using first-morning urine, the test measures the level of neural thread protein -- a protein, which for the past decade, has been linked to the disease.

Test results for patients who had Alzheimer's disease and symptoms for more than a year were significantly higher than those who had symptoms for less than a year, and were even more marked when compared to the age-matched control patients.

The test is available through Nymox's clinical reference laboratory for $295.

Other Sources: Nymox Pharmaceutical Corp.